Novel retinoic acid derivative induces differentiation and growth arrest in neuroblastoma
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Mar 2020 · 1 min read
In brief
In brief
Novel rexinoid compound 6-Methyl-UAB30 demonstrates superior anti-tumor activity in neuroblastoma through multiple mechanisms including growth inhibition, differentiation induction, and stem cell marker suppression. Preclinical studies show decreased proliferation, cell cycle arrest, and improved survival in xenograft models, suggesting potential as a less toxic alternative to standard retinoic acid maintenance therapy.
Written by the GCMD Library team from the article.
Introduction
Retinoic acid (RA) is a differentiating agent utilized as maintenance therapy for high-risk neuroblastoma (NB), but associated toxicities limit its use. We have previously shown that a non-toxic, novel rexinoid, 9-cis-UAB30 (UAB30), decreased NB cell proliferation and in vivo tumor growth. A second generation, mono-methylated compound, 6-Methyl-UAB30 (6-Me), has been recently designed having greater potency compared with UAB30. In the current study, we hypothesized that 6-Me would inhibit NB cell proliferation and survival and induce differentiation and cell-cycle arrest.
Methods
Proliferation and viability were measured in four human NB cell lines following treatment with UAB30 or 6-Me. Cell-cycle was analyzed and tumor cell stemness was evaluated with extreme limiting dilution assays and immunoblotting for expression of stem cell markers. A xenograft murine model was utilized to study the effects of 6-Me in vivo.
Results
Treatment with 6-Me led to decreased proliferation and viability, induced cell cycle arrest, and increased neurite outgrowth, indicating differentiation of surviving cells. Furthermore, treatment with 6-Me decreased tumorsphere formation and expression of stem cell markers. Finally, inhibition of tumor growth and increased animal survival was observed in vivo following treatment with 6-Me.
Conclusion
These results indicate a potential therapeutic role for this novel rexinoid in neuroblastoma treatment.